UPOTREBA POLIETILENSKOG GLIKOLA (6000) ZA DEAKTIVIRANJE TANINA U LIŠĆU DRVEĆA ZA BRŠĆENJE U ISTOČNOJ LIBIJI

This study was conducted to investigate the effect of different levels of Polyethylene glycol (PEG) on in vitro gas production of some tree leaves grown in Eastern Libya. The samples used were Ceratonia siliqua, Pistacia lentiscus, and Acacia cyanophylla. They were incubated anaerobically with rumen liquor from growing male sheep equipped with a permanent cannula. Cumulative gas production was measured after 3, 6, 12, 24, 48 and 72 hours from the incubation of samples with rumen liquor. PEG was added at levels 15, 30 and 45 mg per 0.2 g dry matter. The chemical analysis showed that the crude protein (%) was 8.2, 9.5, 13.4, for P. lentiscus, C. siliqua and A. cyanophylla, respectively, and that of the ether extracts were nearly the same in all the studied samples. The NDF contents were ranged between 44.5% for C. siliqua and 37% for A. cyanophylla with P. lentiscus lie in the middle (39.8%). The percentages of condensed tannins were 25.4, 21.5 and 4.1 for A. cyanophylla, P. lentiscus and C.siliqua respectively. The average cumulative gas production (ml/0.2 g DM) after 48h of incubation was higher (P<0.05) for C. siliqua then P. lentiscus followed by A. cyanophylla (22.9, 12.6 and 8.2) respectively. Addition of Polyethylene glycol (15, 30 and 45 mg PEG/0.2 g DM) increased (P<0.05) the cumulative gas production compared with control (13.5, 16.4 and 20 vs. 8.4). The current study concluded that PEG can be used to alleviate the undesirable effects of anti-nutritional Polyphenols found in some grazing tree leaves.Ovo je istraživanje provedeno radi ispitivanja djelovanja raznih razina polietilenskog glikola (PEG) na in vitro proizvodnju plina lišća nekog drveća što raste u Istočnoj Libiji. Upotrijebljeni uzorci bili su Ceratonia siliqua, Pistacia lentiscus i Acacia cyanophylla. Uzorci su inkubirani anaerobno s tekućinom iz buraga muških ovaca u porastu s trajno ugrađenom kanilom. Nakupljeni plin mjeren je nakon 3, 6, 12, 24, 48 i 72 sata od inkubacije uzoraka s tekućinom iz buraga. PEG je dodan u razinama od 15,30 i 45 mg na 0,2 g suhe tvari. Kemijska analiza je pokazala da su vrijednosti sirovih bjelančevina iznosile 8.2, 9.5 i 13.4 za P.lentiscus, C.siliqua odnosno A.cyanophylla, a bjelančevine drugih ekstrakata bile su gotovo iste u svim ispitivanim uzorcima. Sadržaj NDF iznosio je 44,5% za C.siliqua i 37% za A.cyanophylla dok je P.lentiscus bio u sredini (39,8%). Ostatci kondenziranih tanina bili su 25.4, 21.5 i 4,1 za A.cyanophylla, P.lentiscus odnosno C.siliqua. Prosječni nakupljeni plin (ml/0,2 g DM) nakon inkubacije od 48h bio je viši(P<0,05) za C.siliqua zatim slijede P.lentiscus i A.cyanophylla (22.9,12.6 i 8.2).Dodavanje polietilenskog glikola (15,30 i 45 mg PEG/0.2 g DM) povisilo je (P<0,05) ukupnu proizvodnju plina u usporedbi s kontrolom (13.5,16.4 i 20 vs.8.4). Prema ovom istraživaanju PRG se može upotrijebiti za ublažavanje nepoželjnog djelovanja antinutritivnih polifenola što se nalaze u lišću drveća za bršćenje

Patient-individual hip cups: simulation-based design and sheet metal forming manufacturing

The revision of an hip prosthesis can have different reasons. One frequent cause, especialley after implantation of a conventional cup, is the so called stress-shielding effect which can lead to a migration or loosening. Patientspecific hip cups can be used to counteract this. However, individual hip cups are only implanted for the treatment of great deformations or tumours because of the cost-intensive manufacturing. Within this project a patient-specific hip cup prosthesis has to be developed and manufactured. Besides the numerical design by means of a coupling between multi-body simulation (MBS) and finite element method (FEM), an inovative concept for the production of patientindividual hip prosthesis out of titanium sheets is introduced in this study.DF

Hiding and Confining Charges via "Tube-like" Wormholes

We describe two interesting effects in wormhole physics. First, we find that a genuinely charged matter source may appear neutral to an external observer - a phenomenon opposite to the famous Misner-Wheeler "charge without charge" effect. This phenomenon takes place when coupling a bulk gravity/nonlinear-gauge-field system to a charged lightlike brane as a matter source. The "charge-hiding" effect occurs in a wormhole solution which connects a non-compact "universe", comprising the exterior region of Schwarzschild-(anti-)de-Sitter (SdS) or purely Schwarzschild black hole beyond the Schwarzschild horizon, to a Levi-Civita-Bertotti-Robinson-type (LCBR) "tube-like" "universe" via a wormhole "throat" occupied by the brane. In this solution the whole electric flux produced by the brane is expelled into the "tube-like" "universe" and the brane is detected as neutral by an observer in the non-compact "universe". Next, we find a truly charge-confining wormhole solution when we couple the bulk gravity/nonlinear-gauge-field system to two oppositely charged lightlike branes. The latter system possesses a "two-throat" wormhole solution, where the "left-most" and the "right-most" "universes" are two identical copies of the exterior region of SdS black hole beyond the Schwarzschild horizon, whereas the "middle" "universe" is of LCBR "tube-like" form with geometry dS_2 x S^2. It comprises the finite-extent intermediate region of dS_2 between its two horizons. Both "throats" are occupied by the two oppositely charged lightlike branes and the whole electric flux produced by the latter is confined entirely within the middle "tube-like" "universe". A crucial ingredient is the special form of the nonlinear gauge field action, which contains both the standard Maxwell term as well as a square root of the latter. This theory was previously shown to produce a QCD-like confining dynamics in flat space-time.Comment: 26 pages, 2 figures; v.2 several references added, missing constant factors in few equations inserted, acknowledgement added, results unchanged; v.3 28 pages, several clarifying remarks, references and acknowledgements added, version to appear in International Journal of Modern Physics

Comparing the effect of STan (cardiotocographic electronic fetal monitoring (CTG) plus analysis of the ST segment of the fetal electrocardiogram) with CTG alone on emergency caesarean section rates: study protocol for the STan Australian Randomised controlled Trial (START).

BACKGROUND: Cardiotocography is almost ubiquitous in its use in intrapartum care. Although it has been demonstrated that there is some benefit from continuous intrapartum fetal monitoring using cardiotocography, there is also an increased risk of caesarean section which is accompanied by short-term and long-term risks to the mother and child. There is considerable potential to reduce unnecessary operative delivery with up to a 60% false positive diagnosis of fetal distress using cardiotocography alone. ST analysis of the fetal electrocardiogram is a promising adjunct to cardiotocography alone, and permits detection of metabolic acidosis of the fetus, potentially reducing false positive diagnosis of fetal distress. METHODS: This study will be a single-centre, parallel-group, randomised controlled trial, conducted over 3 years. The primary hypothesis will be that the proportion of women with an emergency caesarean section on ST analysis will not equal that for women on cardiotocography monitoring alone. Participants will be recruited at the Women's and Children's Hospital, a high-risk specialty facility with approximately 5000 deliveries per annum. A total of 1818 women will be randomised to the treatment or conventional arm with an allocation ratio of 1:1, stratified by parity. The primary outcome is emergency caesarean section (yes/no). Statistical analysis will follow standard methods for randomised trials and will be performed on an intention-to-treat basis. Secondary maternal and neonatal outcomes will also be analysed. Additional study outcomes include psychosocial outcomes, patient preferences and cost-effectiveness. DISCUSSION: Approximately 20% of Australian babies are delivered by emergency caesarean section. This will be the first Australian trial to examine ST analysis of the fetal electrocardiogram as an adjunct to cardiotocography as a potential method for reducing this proportion. The trial will be among the first to comprehensively examine ST analysis, taking into account the impact on psychosocial well-being as well as cost-effectiveness. This research will provide Australian evidence for clinical practice and guideline development as well as for policy-makers and consumers to make informed, evidence-based choices about care in labour. TRIAL REGISTRATION: ANZCTR, ACTRN1261800006268 . Registered on 19 January 2018

On the Complexity of Query Result Diversification

Query result diversification is a bi-criteria optimization problem for ranking query results. Given a database D, a query Q and a positive integer k, it is to find a set of k tuples from Q(D) such that the tuples are as relevant as possible to the query, and at the same time, as diverse as possible to each other. Subsets of Q(D) are ranked by an objective function defined in terms of relevance and diversity. Query result diversification has found a variety of applications in databases, information retrieval and operations research. This paper studies the complexity of result diversification for relational queries. We identify three problems in connection with query result diversification, to determine whether there exists a set of k tuples that is ranked above a bound with respect to relevance and diversity, to assess the rank of a given k-element set, and to count how many k-element sets are ranked above a given bound. We study these problems for a variety of query languages and for three objective functions. We establish the upper and lower bounds of these problems, all matching, for both combined complexity and data complexity. We also investigate several special settings of these problems, identifying tractable cases. 1

The impact of excision of benign nonendometriotic ovarian cysts on ovarian reserve: a systematic review

Background Benign nonendometriotic ovarian cysts are very common and often require surgical excision. However, there has been a growing concern over the possible damaging effect of this surgery on ovarian reserve. Objective The aim of this metaanalysis was to investigate the impact of excision of benign nonendometriotic ovarian cysts on ovarian reserve as determined by serum anti-Müllerian hormone level. Data Sources MEDLINE, Scopus, ScienceDirect, and Embase were searched electronically. Study Design All prospective and retrospective cohort studies as well as randomized trials that analyzed changes of serum anti-Müllerian hormone concentrations after excision of benign nonendometriotic cysts were eligible. Twenty-five studies were identified, of which 10 were included in this analysis. Data Extraction Two reviewers performed the data extraction independently. Results A pooled analysis of 367 patients showed a statistically significant decline in serum anti-Müllerian hormone concentration after ovarian cystectomy (weighted mean difference, –1.14 ng/mL; 95% confidence interval, –1.36 to –0.92; I2 = 43%). Subgroup analysis including studies with a 3-month follow-up, studies using Gen II anti-Müllerian hormone assay and studies using IOT anti-Müllerian hormone assay improved heterogeneity and still showed significant postoperative decline of circulating anti-Müllerian hormone (weighted mean difference, –1.44 [95% confidence interval, –1.71 to –1.1; I2 = 0%], –0.88 [95% confidence interval, –1.71 to –0.04; I2 = 0%], and –1.56 [95% confidence interval, –2.44 to –0.69; I2 = 22%], respectively). Sensitivity analysis including studies with low risk of bias and excluding studies with possible confounding factors still showed a significant decline in circulating anti-Müllerian hormone. Conclusion Excision of benign nonendometriotic ovarian cyst(s) seems to result in a marked reduction of circulating anti-Müllerian hormone. It remains to be established whether this reflects a real compromise to ovarian reserve

A Pharmaceutical Paradigm for Cardiovascular Composite Risk Assessment Using Novel Radiogenomics Risk Predictors in Precision Explainable Artificial Intelligence Framework: Clinical Trial Tool

Cardiovascular disease (CVD) is challenging to diagnose and treat since symptoms appear late during the progression of atherosclerosis. Conventional risk factors alone are not always sufficient to properly categorize at-risk patients, and clinical risk scores are inadequate in predicting cardiac events. Integrating genomic-based biomarkers (GBBM) found in plasma/serum samples with novel non-invasive radiomics-based biomarkers (RBBM) such as plaque area, plaque burden, and maximum plaque height can improve composite CVD risk prediction in the pharmaceutical paradigm. These biomarkers consider several pathways involved in the pathophysiology of atherosclerosis disease leading to CVD.This review proposes two hypotheses: (i) The composite biomarkers are strongly correlated and can be used to detect the severity of CVD/Stroke precisely, and (ii) an explainable artificial intelligence (XAI)-based composite risk CVD/Stroke model with survival analysis using deep learning (DL) can predict in preventive, precision, and personalized (aiP3) framework benefiting the pharmaceutical paradigm.The PRISMA search technique resulted in 214 studies assessing composite biomarkers using radiogenomics for CVD/Stroke. The study presents a XAI model using AtheroEdgeTM 4.0 to determine the risk of CVD/Stroke in the pharmaceutical framework using the radiogenomics biomarkers.Our observations suggest that the composite CVD risk biomarkers using radiogenomics provide a new dimension to CVD/Stroke risk assessment. The proposed review suggests a unique, unbiased, and XAI model based on AtheroEdgeTM 4.0 that can predict the composite risk of CVD/Stroke using radiogenomics in the pharmaceutical paradigm

Matrix Models, Geometric Engineering and Elliptic Genera

We compute the prepotential of N=2 supersymmetric gauge theories in four dimensions obtained by toroidal compactifications of gauge theories from 6 dimensions, as a function of Kahler and complex moduli of T^2. We use three different methods to obtain this: matrix models, geometric engineering and instanton calculus. Matrix model approach involves summing up planar diagrams of an associated gauge theory on T^2. Geometric engineering involves considering F-theory on elliptic threefolds, and using topological vertex to sum up worldsheet instantons. Instanton calculus involves computation of elliptic genera of instanton moduli spaces on R^4. We study the compactifications of N=2* theory in detail and establish equivalence of all these three approaches in this case. As a byproduct we geometrically engineer theories with massive adjoint fields. As one application, we show that the moduli space of mass deformed M5-branes wrapped on T^2 combines the Kahler and complex moduli of T^2 and the mass parameter into the period matrix of a genus 2 curve.Comment: 90 pages, Late

Polygenic Risk Score for Cardiovascular Diseases in Artificial Intelligence Paradigm

Cardiovascular disease (CVD) related mortality and morbidity heavily strain society. The relationship between external risk factors and our genetics have not been well established. It is widely acknowledged that environmental influence and individual behaviours play a significant role in CVD vulnerability, leading to the development of polygenic risk scores (PRS). We employed the PRISMA search method to locate pertinent research and literature to extensively review artificial intelligence (AI)-based PRS models for CVD risk prediction. Furthermore, we analyzed and compared conventional vs. AI-based solutions for PRS. We summarized the recent advances in our understanding of the use of AI-based PRS for risk prediction of CVD. Our study proposes three hypotheses: i) Multiple genetic variations and risk factors can be incorporated into AI-based PRS to improve the accuracy of CVD risk predicting. ii) AI-based PRS for CVD circumvents the drawbacks of conventional PRS calculators by incorporating a larger variety of genetic and non-genetic components, allowing for more precise and individualised risk estimations. iii) Using AI approaches, it is possible to significantly reduce the dimensionality of huge genomic datasets, resulting in more accurate and effective disease risk prediction models. Our study highlighted that the AI-PRS model outperformed traditional PRS calculators in predicting CVD risk. Furthermore, using AI-based methods to calculate PRS may increase the precision of risk predictions for CVD and have significant ramifications for individualized prevention and treatment plans

A Pharmaceutical Paradigm for Cardiovascular Composite Risk Assessment Using Novel Radiogenomics Risk Predictors in Precision Explainable Artificial Intelligence Framework: Clinical Trial Tool

Background: Cardiovascular disease (CVD) is challenging to diagnose and treat since symptoms appear late during the progression of atherosclerosis. Conventional risk factors alone are not always sufficient to properly categorize at-risk patients, and clinical risk scores are inadequate in predicting cardiac events. Integrating genomic-based biomarkers (GBBM) found in plasma/serum samples with novel non-invasive radiomics-based biomarkers (RBBM) such as plaque area, plaque burden, and maximum plaque height can improve composite CVD risk prediction in the pharmaceutical paradigm. These biomarkers consider several pathways involved in the pathophysiology of atherosclerosis disease leading to CVD. Objective: This review proposes two hypotheses: (i) The composite biomarkers are strongly correlated and can be used to detect the severity of CVD/Stroke precisely, and (ii) an explainable artificial intelligence (XAI)-based composite risk CVD/Stroke model with survival analysis using deep learning (DL) can predict in preventive, precision, and personalized (aiP 3 ) framework benefiting the pharmaceutical paradigm. Method: The PRISMA search technique resulted in 214 studies assessing composite biomarkers using radiogenomics for CVD/Stroke. The study presents a XAI model using AtheroEdge TM 4.0 to determine the risk of CVD/Stroke in the pharmaceutical framework using the radiogenomics biomarkers. Conclusions: Our observations suggest that the composite CVD risk biomarkers using radiogenomics provide a new dimension to CVD/Stroke risk assessment. The proposed review suggests a unique, unbiased, and XAI model based on AtheroEdge TM 4.0 that can predict the composite risk of CVD/Stroke using radiogenomics in the pharmaceutical paradigm